COVID Vaccine Responses Limited in Blood Cancer Patients
COVID Vaccine Responses Limited in Blood Cancer Patients image
COVID Vaccine Responses Limited in Blood Cancer Patients
Posted Apr 14, 2021

According to investigators at the University of Pennsylvania School of Medicine, a large percentage of blood cancer patients do not develop adequate antibodies to the COVID-19 vaccines. The study results were based on a small number (28) of hematologic blood cancer patients. 

It has been unclear how blood cancer and myeloma patients will respond to the COVID vaccines. Will sufficient antibodies be developed? Blood cancer patients were not allowed to be included in the initial COVID-19 clinical trials. This lingering research question is an important one for myeloma patients as communities across the world open back up.

Blood cancer patients are at higher risk of COVID complications, with mortality rates exceeding 30%. Blood cancer patients can also develop prolonged shedding of infectious COVID-19, often lasting several months. It makes sense that blood cancer patients should be first in line for the vaccines. 

The investigators studied COVID-19 antibody responses in 28 blood cancer patients [CLL (29.4%), Lymphoma (31.3%), multiple myeloma (43%) and other myeloid malignancies (5.97%)] seen at UPMC Hillman Cancer Center who had received two doses of either the Moderna or Pfizer vaccine. Median time between the two doses was 23 days. Patients with prior COVID-19 were excluded. 

Thirty patients (44.8%) were in active treatment and 37 (55.2%) were under observation or in remission.

Antibody tests were performed at the UPCM clinical laboratories using the Beckman Coulter SARTS-CoV-2 platform which detects IgG levels. 

In total 31 patients (46%) had negative antibody results after vaccination and were considered to be vaccine non-responders. Older patients were more likely to be vaccine non-responders than younger patients. Other factors like IgG levels, number of days between vaccine doses, cancer therapy and antibody measurement did not differ between vaccine responders vs. non-responders. CLL patients were more likely to be non-responders, even when in remission. 

What does this mean for myeloma patients? It is still important to get the COVID-19 vaccine as there is greater than a 50% chance of it working for you (the CLL patient results increased the % of non-responders). With further study of just multiple myeloma patients, it should become more clear. Asking your doctor for an antibody test to see if you have developed COVID-19 antibodies post-vaccine is a good idea. 

Until more data comes out specifically for myeloma patients, we should continue to wear masks and observe social distancing regardless of vaccination status.

Note: The original publication has not yet been peer reviewed. 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811